Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 17Oropharyngeal Neoplasms 11Nasopharyngeal Carcinoma 11Prostatic Neoplasms 7Laryngeal Neoplasms 7Mouth Neoplasms 6Hypopharyngeal Neoplasms 6Carcinoma 6Rectal Neoplasms 5Head and Neck Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Esophageal Neoplasms 3Carcinoma, Squamous Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Salivary Gland Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Nasopharyngeal Neoplasms 2Mesothelioma 2Epstein-Barr Virus Infections 2Carcinoma, Intraductal, Noninfiltrating 2Astrocytoma 2Anus Neoplasms 2Vaginal Neoplasms 1Urothelial Carcinoma of the Bladder 1Tongue Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomatitis 1Stomach Neoplasms 1

Interventions

pembrolizumab 1Radiotherapy, Intensity-Modulated 1Losartan 1LY3300054 1Gemcitabine 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Camurati-Engelmann Syndrome × Radiotherapy, Intensity-Modulated × 90 days × Clear all
NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡